At GANYMED, we are dedicated to the delivery of a new class of highly effective truly cancer specific ideal monoclonal antibody therapeutics (iMAB) against solid cancers with high medical need.

In order to do this, we have brought together the strongest and most dynamic scientific team for translational medicine.

We have generated a sustainable pipeline of iMABs that we are developing as high value therapeutics for solid cancers with huge unmet clinical need, such as gastric, oesophageal, pancreatic, breast, colorectal, prostate and lung cancer.

Contact Information: GANYMED Pharmaceuticals AG Freiligrathstrasse 12 D-55131 Mainz Phone: Fax: E-Mail: +49 (0) 6131 / 1440 - 100 +49 (0) 6131 / 1440 - 114 info[at]ganymed-pharmaceuticals.com